新京报讯（记者王卡拉）10月16日，"心舒华夏—心肌病卓越诊疗全国示范项目"在北京落地，也标志着 北京首个肥厚型心肌病门诊在安贞医院正式启用。新门诊将为心肌病，特别是致死风险较高的肥厚型心 肌病，打通筛查、诊断、管理的快捷路径，并构建起一体化的规范化诊疗体系，能有效解决心肌病患者 日常诊疗中的痛点，也将为跨区域乃至全国范围打造示范蓝本。 马长生介绍，肥厚型心肌病门诊的成立，将以精准诊疗为引擎，构建从筛查、诊断到长期管理的一体 化、规范化诊疗新路径，为患者的症状改善、预后改善、综合长期管理提供强有力的平台；同时也为中 国在肥厚型心肌病的研究上增加更多资源、更多机会，围绕肥厚型心肌病进行高质量的临床研究，从而 进一步转化改变临床实践。 对于项目的未来规划，蔡军表示，目前在心肌病的发病机制、创新药物研发、创新手术治疗等方面，仍 存在很多问题，值得进一步探索。未来计划以该项目为核心支点，将中心真正建设成为技术创新、人才 培养和科学研究的高地，最终实现国际先进经验本土化，规范管理经验全国化，推动整个中国的心肌病 亚专科的发展。 封面图片/医院供图 校对 陈荻雁 心肌病是一类严重的心脏疾病，会直接损害心肌的结构与功能，对 ...

新京报讯（记者王卡拉）在当前医疗健康领域的发展进程中，患者声音及其参与正逐步成为环境塑造与 医疗决策的重要驱动力。然而，如何进一步将这些探索性成果持续巩固使其体系化、标准化，依然是行 业需深入探讨和共同面对的长期课题。在近日举行的第三届诺华中国患者日活动上，中国疾控中心慢病 中心主任吴静表示，慢性病负担重、病程长、成因复杂，其治理必须依托多部门协作与全民参与。让患 者参与到政策制定与实施过程，有助于弥合政策制定与真实需求之间的鸿沟，结合循证科学，提高政策 的精准性与可操作性，促进医患协同并优化落实效果。 本次活动以"聚能患者，引领未来"为主题，汇聚了来自产业界、学术界、研究机构的专家学者、行业伙 伴及患者组织代表，共同探索以患者为核心的医疗健康新未来。 校对 赵琳 近年来，从国际经验到本土探索，多方协作已为患者关怀生态建设提供了丰富的案例和可行路径。随着 时代发展和技术进步，合作模式也在持续优化以满足不断变化的需求。通过整合前沿实践与数字化发展 趋势，患者组织有望进一步扩大服务覆盖与影响力，提升协同效率与专业化水平，并更好地满足患者真 实需求。 "患者组织了解患者需求，企业掌握药物研发与创新，数字化服务平台带 ...

Core Points - The 2025 Financial Street Forum Annual Conference will be held from October 27 to 30 in Beijing, focusing on "Global Financial Development under Innovation, Transformation, and Restructuring" [1][3] - Over 400 important guests from more than 30 countries and regions are expected to attend, with significant national financial policies to be announced during the event [1][2] Group 1 - The forum, established in 2012, has successfully held 13 sessions and is recognized as a barometer for China's financial reform and development [2] - The conference aims to promote high-quality global financial development, calling for innovation consensus, transformative momentum, and restructuring actions to build a more resilient, inclusive, and sustainable global financial system [3] Group 2 - Key financial regulatory leaders, including the Governor of the People's Bank of China and heads of financial regulatory agencies, will attend and speak at the conference [4] - The event will feature a framework of "main forum + parallel forums + fintech conference + supporting activities," with 27 topic activities and 6 investment and financing matching activities planned [5] Group 3 - The opening ceremony is scheduled for the afternoon of October 27, with major leaders delivering speeches, while the closing ceremony on October 30 will focus on "International Economic and Trade Resilience Cooperation" [6] - Four key areas of focus for this year's forum include the release of important national financial policies, deepening international cooperation, enhancing financial services for the real economy, and the concentrated release of forum outcomes [7][8]

这意味着，良品铺子易主武汉国资一事"告吹"。记者注意到，良品铺子首次披露关于筹划控制权变更事 项的停牌公告是在7月10日晚上，宣告协议终止是在10月16日晚上。东方财富数据显示，7月11日至10月 16日期间，良品铺子的总市值累计减少约3.89亿元。 新京报贝壳财经讯（记者阎侠）10月17日，良品铺子的股价开盘即下跌，截至午间收盘，其股价为 12.52元/股，跌幅为1.73%，公司总市值约50.21亿元。 编辑 杨娟娟 消息面上，良品铺子披露了关于控股股东及其一致行动人终止控制权转让的公告。 校对 杨利 时间回拨到2025年7月17日，武汉长江国际贸易集团有限公司（简称"长江国贸"）与良品铺子控股股东 宁波汉意创业投资合伙企业（有限合伙）（简称"宁波汉意"）及其合伙人杨红春、杨银芬、张国强、潘 继红，以及宁波汉意一致行动人宁波良品投资管理有限公司（简称"良品投资"）及其股东杨红春、杨银 芬、张国强签订了《关于良品铺子股份有限公司之附生效条件的股份转让协议》。 根据协议，若本次交易顺利完成，将导致良品铺子控股股东及实际控制人发生变化，公司控股股东将由 宁波汉意变更为长江国贸，实际控制人将由杨红春、杨银芬、张国强 ...

Core Insights - The 2023 Double 11 shopping festival has evolved into a two-month commercial event, marking a significant shift in the e-commerce landscape [1][4] - Major platforms like Tmall, JD.com, Douyin, and Xiaohongshu are adopting new strategies to enhance user experience and engagement, focusing on a more straightforward promotional approach [2][8] E-commerce Trends - Tmall's Double 11 pre-sale saw 35 brands achieving over 100 million yuan in sales within the first hour, with 1,802 brands doubling their sales compared to the previous year [5] - JD.com reported a 47.6% year-on-year increase in active users during the Double 11 period, with significant growth in categories like home appliances and electronics [5] - Xiaohongshu's marketplace saw a 77% increase in the number of buyers and a 73% increase in transaction orders within the first 48 hours of Double 11 [5] AI Integration - This year's Double 11 is characterized as the first "AI-driven" event, with platforms leveraging AI for product recommendations and user engagement [11][12] - Tmall and JD.com are utilizing AI tools to enhance user experience, with JD.com reporting significant growth in sales for AI-related products [11][12] Competitive Landscape - The competition among e-commerce platforms is intensifying, with a shift from price wars to a focus on product quality and user experience [15] - The integration of content platforms into e-commerce is diversifying the competitive landscape, with Douyin and Xiaohongshu leveraging their content ecosystems to attract users [10][14] Consumer Behavior - Consumers are shifting from seeking low prices to prioritizing quality, leading to a transformation in the competitive focus of platforms and merchants [15] - The trend towards rational consumption is reshaping the e-commerce competition, emphasizing the importance of user engagement and service quality [2][7]

Core Viewpoint - Kanghua Biotech reported a significant decline in performance for Q3 2025, with net profit dropping over 50% year-on-year, raising concerns about the company's ability to meet its profit commitments for 2025-2026 [1][2]. Financial Performance - For Q3 2025, Kanghua Biotech achieved total revenue of 840 million yuan, a year-on-year decrease of 20.78%, and a net profit of 189 million yuan, down 53.41% year-on-year [1]. - Excluding last year's one-time revenue from overseas licensing of the six-valent norovirus vaccine (106 million yuan), revenue decreased by 11.96% year-on-year, with non-immunization vaccine sales also down by 11.97% [1]. - The company’s net profit, excluding non-recurring gains and losses, fell by 43.12% compared to the same period last year [1]. Product Portfolio and Market Challenges - Kanghua Biotech currently has only two marketed products: the human rabies vaccine and the ACYW135 meningococcal polysaccharide vaccine, with the rabies vaccine accounting for over 97% of total revenue in 2024 [1][2]. - The company experienced a sharp decline in the batch release volume of its core product, the human rabies vaccine, which dropped by 43.83% year-on-year [2]. Shareholding Changes - On July 18, 2025, Kanghua Biotech's major shareholders signed a share transfer agreement with Wankexin Biotech, transferring 21.91% of the company's shares, resulting in Wankexin Biotech becoming the controlling shareholder [3][4]. - Following the share transfer, Wankexin Biotech will hold 29.99% of the voting rights, and the company will have no actual controller [4]. Performance Commitments and R&D - Kanghua Biotech made a performance commitment to achieve a net profit of no less than 728 million yuan for 2025 and 2026, with a minimum of 260 million yuan allocated for R&D expenses [5]. - The company reported a non-recurring net profit of 71.76 million yuan for the reporting period, a decrease of 30.82% year-on-year [6]. Future Growth Prospects - To meet its profit commitments, Kanghua Biotech urgently needs to launch new products, with seven projects in its R&D pipeline, including six vaccine candidates [7]. - The six-valent norovirus vaccine is expected to enter clinical trials by December 2024, and the company has signed an exclusive licensing agreement with HilleVax for international commercialization [7]. - Kanghua Biotech is exploring various strategies to enrich its product pipeline, including product agency, investment, and mergers and acquisitions [8].

Core Insights - Porsche's electric vehicle (EV) strategy faces challenges with aggressive targets and slow implementation, as the Cayenne Electric begins road testing and is expected to launch in 2026 [1] - The company aims for over 50% of new cars to be electric by 2025 and over 80% by 2030, but only 27% of deliveries in 2024 are expected to be EVs [1][2] - Sales have declined significantly, with a 6.1% drop in new car deliveries in the first half of 2025 and a 26% decrease in the crucial Chinese market [1][2] Sales and Financial Performance - Porsche's sales revenue for the first half of 2025 was €18.16 billion, a 6.7% decline, marking the first half-year drop since 2020 [3] - Operating profit fell to €1.01 billion, a staggering 67% decrease year-on-year [3][4] - The decline in sales is attributed to high R&D costs for EVs, underperformance in sales, and weak demand for traditional fuel vehicles [4] Product Development and Market Position - Porsche currently has two electric models: the Taycan and the Macan Electric, with the latter not expected to deliver until 2024 [2] - The Taycan has sold over 150,000 units since its launch, but the overall EV sales have not met expectations, with less than 15% of deliveries being electric vehicles [2] - The company faces competition from local Chinese manufacturers that offer advanced smart features and competitive pricing, impacting Porsche's market position [5][6] Strategic Adjustments - In September 2023, Porsche announced delays in several new EV models and extended the production life of internal combustion and hybrid vehicles for the next decade [7] - The company plans to launch the pure electric 718 by 2027 and enhance local market adaptations, including integrating local applications into their vehicles [7][8] - A global efficiency optimization plan aims to reduce approximately 3,900 jobs, saving €800 million in operational costs over the coming years [9]

Core Insights - The global automotive industry is undergoing a profound transformation, with China positioned at the center of this change, characterized by rapid technological iteration and shifts in management models and competitive landscapes [1] Group 1: Industry Transformation - The automotive industry is experiencing a deep transformation, with a focus on speed as the key factor driving change [1] - Market competition and evolving user demands are fundamental drivers of transformation for companies like GAC Group [1] Group 2: GAC Group's Strategic Initiatives - GAC Group plans to launch the "Panyu Action" by the end of 2024, aiming for a sales target of 2 million units for its self-owned brands by 2027 [1] - The shift from traditional fuel vehicles to new energy vehicles requires meeting user expectations for performance, such as achieving 0-100 km/h acceleration in 6 seconds [1] - GAC Group is transitioning from a traditional manufacturing enterprise to a "new GAC" driven by both user-centric and technology-focused approaches [1] Group 3: Collaborative Efforts - GAC Group emphasizes the importance of open collaboration in the smart connected vehicle era, partnering with JD.com and CATL to develop a new vehicle tailored to user scenarios [2] - The new vehicle will integrate GAC's manufacturing capabilities, CATL's battery technology, and user insights from JD.com, focusing on safety, battery, and service innovations [2] - GAC Group is prioritizing the development of the high-end smart electric vehicle brand "Qijing" in collaboration with Huawei, with the first model set to launch next year [2]

Core Points - Dongfeng Yipai officially launched the 2026 models of Nano 01 and eπ008 five-seater, with starting prices of 58,800 yuan and 159,900 yuan respectively [1] - The cumulative delivery of Dongfeng Nano 01 has exceeded 100,000 units, with exports to 40 countries and regions [1] - As of September, the total sales of Dongfeng Yipai's four models have surpassed 100,000 units [1] Model Upgrades - The 2026 Nano 01 underwent over 280 upgrades, including the introduction of a new color "Elf Green" and a new vehicle system that supports multi-command dialogue [2] - The new model features L2-level assisted driving capabilities and is equipped with the Mahle E ten-in-one electric drive system, offering a maximum range of 430 km [2] eπ008 Specifications - The 2026 eπ008 five-seater has a wheelbase of 3025 mm and features second-row electric "magic carpet" seats, with trunk space expandable from 783L to 1876L [5] - The eπ008 includes multiple upgrades in smart features, such as dynamic traffic light countdown, route search, and voice broadcasting in navigation [5]

Core Viewpoint - The ultimate goal of intelligent technology is to "serve people," shifting product development from being defined by automakers to being user-defined, focusing on practical needs and emotional value [1] Group 1: Company Developments - BAIC Group's Chairman Zhang Jianyong announced the launch of the new Alpha T5, which features an integrated cockpit and driving architecture, enabling full-scene automatic navigation assistance for mainstream market users priced between 100,000 to 150,000 yuan, set to be released at the end of October [1] - In the L3 level domain, BAIC received the first batch of L3 road test licenses in Beijing in 2023 and was included in the first national pilot program in 2024, with over 110,000 kilometers of testing completed by August this year [2] - BAIC is collaborating with Pony.ai to develop a Robotaxi based on the Alpha T5, which has already demonstrated operations in July this year, with plans for a thousand units to be operational by the end of the year [2] Group 2: Industry Challenges and Initiatives - Despite breakthroughs in the domestic intelligent connected vehicle industry, challenges such as insufficient policy coordination, technological silos, and supply chain risks remain, requiring collective efforts from the entire industry [3] - Zhang proposed two initiatives: first, to promote policy coordination to eliminate cross-regional implementation barriers and accelerate the definition of L3 responsibility boundaries; second, to deepen technology sharing by establishing an industry-level autonomous driving data pool and a testing resource platform [3] - The development of intelligent connected vehicles is described as a marathon requiring long-term technological planning, an open mindset for collaboration, and a commitment to safety [4]